Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs

Elisa Lenotti1, Andrea Alberti1, Francesca Spada2, Vito Amoroso1, Patrick Maisonneuve3, Salvatore Grisanti1, Alice Baggi1, Susanna Bianchi1, Nicola Fazio2 and Alfredo Berruti1*†

1 Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, ASST-Spedali Civili, Brescia, Italy, 2 Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, IEO European Institute of Oncology, IRCCS, Milan, Italy, 3 Division of Epidemiology and Biostatistics, IEO European Institute of Oncology, IRCCS, Milan, Italy

Objective: Antiproliferative activity of somatostatin analogs (SSAs) has been demonstrated in digestive neuroendocrine tumors (NETs), but few data have been published in patients with pulmonary NETs. We therefore conducted a retrospective study to provide additional data on the outcome of patients with metastatic lung NETs submitted to front line SSAs.

Research Design and Methods: Patients with metastatic lung NET treated with first line SSA-monotherapy (octreotide or lanreotide) in two different reference Institutions were reviewed. Outcome measures were progression-free survival (PFS) overall survival (OS), overall response rate and safety. We also explored prognostic factors associated with PFS.

Methods: The outcome of consecutive patients (pts) with metastatic lung NETs, who underwent first-line treatment with SSAs, recruited from 2014 on 2019 in two Italian reference Institutions, was retrospectively evaluated.

Results: Thirty-one patients entered the study: 14 (45.2%) with typical and 17 (54.8%) atypical carcinoid. Six patients (19.4%) had a carcinoid syndrome. 60.0% of patients had Ki-67 ≤ 10%. Two (6.5%) patients obtained a partial response, 24 (77.4%) disease stabilization while 5 (16.1%) had progressive disease. Median progression free survival (PFS) was 28.6 months, median overall survival (OS) was not attained. Ki-67 ≤ 10%, typical carcinoid histotype and non-functioning disease, were associated with a non-significant PFS prolongation. PFS in patients with atypical carcinoids and in those with Ki-67 >10% was greater than 19 months.
Carcinoids are very limited and refer to retrospective series (15 regarding the anti-proliferative effects in NET patients. However, the data are well tolerated and have demonstrated both anti-secretory and advanced lung carcinoids, was early stopped for insufﬁcient progression or death whichever occurred (10–12).

In patients with unresectable locally advanced or metastatic disease the goals of medical management are to control both hormone-related symptoms and tumor growth (13). Lung NETs frequently express somatostatin receptors, therefore somatostatin analogs (SSAs), such as lanreotide autogel (LAN) and octreotide long-acting release (LAR), are frequently used therapies and recommended by available guidelines (2, 13, 14). These drugs are well tolerated and have demonstrated both anti-secretory and anti-proliferative effects in NET patients. However, the data regarding the efficacy of SSAs in the management of lung carcinoids are very limited and refer to retrospective series (15–19). No prospective study data is currently available. The SPINET trial (NCT02683941), a placebo-controlled randomised phase III study, which was designed to evaluate lanreotide 120 mg in advanced lung carcinoids, was early stopped for insufficient enrolment (20). Most of the published retrospective studies are heterogeneous and included patients with NET of different primaries (21–28). Only 2 studies evaluated patients with lung carcinoids only. One of them enrolled patients undergoing SSAs both as ﬁrst, and second line approach (21), only one study retrospectively evaluated patients treated with ﬁrst line SSAs (22).

More data on the efﬁcacy of SSAs in patients with advanced lung carcinoids, not previously submitted to systemic antineoplastic therapies, are therefore needed.

This retrospective study was designed to provide additional data on the efﬁcacy of SSAs as ﬁrst line therapy in patients with metastatic lung carcinoids.

**MATERIAL AND METHODS**

We retrospectively reviewed data of consecutive patients with metastatic lung NET, treated with ﬁrst line SSA monotherapy, from January 2014 to December 2019, at the Medical Oncology Unit of ASST Spedali Civili di Brescia and at the Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors of the European Institute of Oncology of Milan (IEO). To be included in the study the patients had to meet the following inclusion criteria: histopathological conﬁrmed diagnosis of Lung NET according to 2015 WHO criteria (22), locally advanced or metastatic disease not amenable to radical surgery, absence of prior systemic therapy, at least three months of SSA therapy. Poorly differentiated morphology was an exclusion criterion. A single investigator (EL) collected clinical data from medical records. Database included the following data at baseline conditions: age, gender, tobacco exposure, surgery of primary tumor, histological subtype according 2015 WHO criteria, Ki-67 index, mitotic count, hereditary or sporadic, primary tumor site. TNM/AJCC (tumor-node-metastasis/American Joint Committee on Cancer 2010 stage) (9), site of metastasis, functional tumor status. The following data were collected before and during the SSA therapy: ECOG PS, disease response at imaging according to RECIST criteria, type of SSA used and dose, date of initiation and completion of SSAs, adverse effects, any local therapies before SSA initiation or during SSA treatment. The study was approved by the institutional review board.

Follow-up visits during SSA therapy were performed approximately every 3 months and included a physical examination, complete blood count and biochemical proﬁle. The evaluation of tumor response was assessed approximately every 6 months. Computed tomography [CT] scan or Positron emission tomography [PET] with Gallium 68 were the imaging techniques employed. The best overall response was deﬁned according to the RECIST 1.1 criteria. Adverse events were evaluated over the whole duration of SSA administration and classiﬁed according to CTCAE v4.0.

Treatment with SSAs consisted in an intramuscular injection of octreotide long-acting release (LAR) (at dose of 20 mg or 30 mg every 4 weeks, or 30 mg every 3 weeks) or a subcutaneous injection of lanreotide depot (at dose of 60 mg or 120 mg every 4 weeks).

The primary study end point was progression free survival (PFS), deﬁned as the time elapsing from SSA initiation to disease progression or death whichever occurred ﬁrst. Patients with no event and alive were censored at the date of the last follow-up. Secondary endpoints were: overall survival (OS), deﬁned as the time from SSA initiation to death from any cause. Survivors were censored at the date of their last follow-up; best overall response under SSA; toxicity.

**Statistical Analysis**

Patient and tumor characteristics, the type of SSA (duration of treatment) and toxicities were described with conventional

**Conclusions:** The long PFS and OS obtained in this case series suggest that SSAs could be effective as ﬁrst line approach in the management of patients with progressive, metastatic pulmonary NET.

**Keywords:** lung carcinoid, somatostatin analog, carcinoid syndrome, prognostic factor, distant metastases
descriptive statistical analysis. Due to the explorative nature of this study, no sample size was determined. Any associations between clinical-pathological features and clinical benefit (partial response and stable disease) to the treatment was tested using the exacted Fisher test. The cut-off date for the analysis was June 2020. Receiver operating characteristic (ROC) curve analysis was used to identify the optimal cut-off value of Ki-67 for the prediction of disease progression (Figure 1). The PFS and OS curves were calculated with the Kaplan-Meier method and compared with the log-rank test. The prognostic value of age, gender, smoking exposure, histological subtype, Ki-67 category, surgery of primary tumor, functional tumor status, metastatic site, time between diagnosis and treatment start and type of SSA were evaluated in relation to PFS. The Cox regression model was used to estimate the hazard ratios (HR) and relevant 95% confidence intervals (CIs). Two-sided p-values are reported and a p-value of 0.05 was considered statistically significant. The statistical analyses were performed using the SAS software version9.4 (SAS Institute Inc. Cary NC, USA).

RESULTS

Data of thirty-one consecutive patients, meeting the eligibility criteria, were analyzed. The clinical and pathological and characteristics and type of SSAs administered are summarized in Table 1.

Figure 1 | ROC curve of Ki67 for the prediction of disease progression. The optimal Ki-67 cut-point maximizing the Youden index for the prediction of disease progression at 28.6 months (median progression free survival) is 10%.

| Table 1 | Patient Characteristics. |
|---|---|
| **PATIENTS CHARACTERISTICS** | **n** |
| Patient number | 31 |
| Median age at SSA initiation | 62 (range 20-82) |
| **Gender** | |
| Female | 18 (58%) |
| Male | 13 (42%) |
| **Tobacco exposure** | |
| Yes | 1 (3%) |
| Previous | 8 (25%) |
| Never | 11 (32%) |
| **ECOG PS** | |
| 0 | 30 (94%) |
| 1 | 1 (6%) |
| **TUMOR CHARACTERISTICS** | |
| **Histological subtype** | |
| Typical carcinoid | 14 (45%) |
| Atypical carcinoid | 17 (55%) |
| **Ki-67** | |
| \( \leq 2\% \) | 5 (20%) |
| 3-20\% | 19 (76%) |
| >20\% | 1 (4%) |
| **Missing** | 6 |
| **Mitotic count** | |
| < 2/2 mm² | 8 (57%) |
| 2-10/2 mm² | 9 (53%) |
| **Missing** | 14 |
| **Necrosis** | |
| Negative | 22 (96%) |
| Positive | 1 (4%) |
| **Missing** | 8 |
| **TTF1** | |
| Negative | 9 (29%) |
| Positive | 11 (35%) |
| **Primary tumor site** | |
| Right | 18 (58%) |
| Left | 10 (32%) |
| Bilateral | 3 (10%) |
| **Functional status** | |
| Carcinoid syndrome | 6 (19%) |
| Non functioning tumors | 25 (81%) |
| **Metastases** | |
| Synchronous | 18 (58%) |
| Metachronous | 13 (42%) |
| **Site of metastases** | |
| Liver | 8 (26%) |
| Liver and other sites | 11 (35%) |
| Bone | 12 (39%) |
| Extra-regional nodes | 6 (19%) |
| Lung | 6 (19%) |
| Peritoneal | 3 (10%) |
| Brain | 1 (3%) |
| Others | 6 (19%) |
| **Number of metastases sites** | |
| 1 organ | 16 (52%) |
| > 1 organ | 15 (48%) |
| **Somatostatin receptor positivity at nuclear medicine imaging** | |
| Ga68-PET/CT | 13 (42%) |
| Octreoscan | 3 (10%) |
| **Primary tumor resected** | |
| Yes | 18 (58%) |
| No | 13 (42%) |

(Continued)
Thirteen (41.9%) patients were male, median age at SSA initiation was 62 years (range 20-82 years). The majority of patients (93.5%) had an ECOG PS 0.

Fourteen patients (45.2%) had a typical carcinoid, 17 (54.8%) an atypical carcinoid. Six patients had a carcinoid syndrome. One tumor, classified as atypical carcinoid, had Ki-67≤20%. This latter tumor was classified as an atypical carcinoid due to the well-differentiated phenotype. Necrosis was described in only one patient (3.2%). Radiological staging at diagnosis was performed with thoracic and abdominal CT in 17 (55%) patients. PET Gallium or Octreoscan were performed in 16 (51.6%) patients. All disease lesions displayed great uptake of the radiotracers.

Metastases were synchronous in 18 (58.1%) patients and metachronous in 13 (41.9%). Eighteen (58.1%) patients underwent surgery of the primary tumor which consisted in lobectomy in 3 patients (9.7%), lobectomy plus lymphadenectomy in 11 patients (35.5%) and atypical resection in 4 others. Liver was the most frequent metastatic site (61.3%). The other metastatic sites were bone (38.7%), contralateral lung (19.4%), extra-regional nodes (19.4%) and peritoneum (9.7%).

**Treatment Administered**

Median time from diagnosis of primary neuroendocrine tumor to SSA therapy start was 13 months (range: 3-82). Twenty-seven (87.1%) patients received octreotide LAR, 26 at the standard dose of 30mg/4 weeks (one of them subsequently switched to a dose of 30mg/3 weeks), and one at standard dose of 20mg/4 weeks. Seven (22.6%) patients received lanreotide depot, six at standard dose of 120mg/28 days and one at 60mg/28 days. Three of them received both Octreotide and Lanreotide, in succession. The median treatment duration was 30 months (range: 3-82). Three patients (9.7%) developed mild diarrhea, no other adverse events were noted.

After a median follow up of 44 months (range 11-103 months), 20 patients (64.5%) underwent disease progression and 17 (54.8%) stopped the SSA therapy. Second line therapies were capecitabine plus temozolomide (CAPTEM regimen) in 7 patients, everolimus in 4 patients and peptide receptor radionuclide therapy (PRRT) in 4 patients. The remaining two patients received best supportive care. At the date of the last follow-up examination, 11 (35.5%) patients were free from progression and still under SSAs.

**Tumor Response, Progression-Free and Overall Survival**

Two patients (6.5%) obtained a partial response (PR), 24 (77.4%) stable disease (SD), whereas five patients (16.1%) had disease progression. After a median follow up of 44 months (range 11-103), the median PFS was 28.6 months (95% confidence interval (CI): 1.5-41.8 months) (**Figure 2**). At the last follow-up examination only two patients died so the median OS was not reached (**Figure 3**). All patients with carcinoids syndrome obtained an efficacious syndrome control (flushing and diarrhea), with complete symptom response in all of them.

A not significant more prolonged PFS was observed in patients with Ki-67 ≤ 10%, typical carcinoid, non-functioning disease, no liver metastases as opposed to their respective counterparts (**Table 2** and **Figure 2**).

None of following parameters were associated with PFS: age (<60 vs ≥60 years), gender, smoking exposure, primary tumor surgery, site of metastasis, time interval between diagnosis and treatment start (<1 vs ≥1 year), SSA administered (octreotide vs lanreotide) (**Table 2**).

**DISCUSSION**

Somatostatin analogs are standard treatment in the management of well-differentiated neuroendocrine tumors of the gastro-entero-pancreatic tract, both functioning and non-functioning. On the basis of the results of the two prospective randomized studies (29, 30), their administration as first line approach is recommended to patients whose tumor expresses ki-67 in less than or equal to 10% of cancer cells (2). No prospective studies of first-line SSA have been conducted in patients with lung NET.

In this retrospective series the 2 SSAs: octreotide and lanreotide, were shown to be active as first line therapy in patients with advanced/metastatic lung NET with a proportion of partial responses and stable diseases not different from that obtained in the GEP NET setting. The good overall survival should be interpreted considering the short follow-up and the few events observed, that limit the generalization of this result. The 28-month PFS is promising, considering that lung carcinoids, in particular atypical ones, generally have a worse prognosis than GEP NET patients (2). The PFS of the present case series is superior to that of a published retrospective study of lung carcinoids submitted to front line SSAs (22). The difference can be attributed to the patient selection and in particular the higher proportion of typical carcinoids in our series, as compared to that of Bongiovanni A et al. (22).

As expected, atypical carcinoid was associated with a lower PFS than typical carcinoid, although not statistically significant. However, the 19 month PFS of patients with atypical carcinoid is a better outcome compared with historical reports (6). As mentioned in the introduction, the efficacy of SSAs was demonstrated in GEP NETs with Ki67 ≤10%. The observed median PFS of 27 months in lung carcinoid patients with Ki67<10% in the present paper is suggestive of efficacy of these drugs also in this subset. This series however...
included 9 patients whose lung carcinoid had a ki67 ranging between 11 and 20% and 1 patient with ki67 >20%. The median PFS of 19.9 months in patients with ki67 >10% is noteworthy and suggests that also selected patients with ki67 >10% could benefit from SSAs administered as frontline therapy. This observation needs confirmation in future prospective studies.

In our series the PFS was negatively influenced by the functional status (although without attaining the statistical significance) confirming a previous observation (22). However, it did not change dividing patients according to the tumor burden and the presence of liver metastases, suggesting that these parameters could not be considered a deterrent in the prescription of SSAs as first-line therapy.

**CONCLUSION**

In summary, the long PFS obtained in this patient series with progressive, metastatic pulmonary NET, uniformly submitted to first line SSAs suggest that these drugs could be potentially efficacious in this patient setting, confirming previous observations (21, 22).
These findings are relevant in patients with Ki67 ≤10% and typical carcinoids, but are encouraging also in patients with greater Ki67 expression and atypical histotype. Although no definitive conclusions can be drawn from our series of patients and that all our outcomes should be interpreted with caution, the results of our analysis are encouraging and should be considered as hypothesis-generating for further prospective studies.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by ethics committee of European Institute of Oncology. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

**AUTHOR CONTRIBUTIONS**

EL, ABe, NF, and FS contributed to conception and design of the study. EL organized the database. PM and AA performed the statistical analysis. AA, EL, and ABe wrote the first draft of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

This study was in part supported by The Italian Ministry of Health with Ricerca Corrente and 5 × 1000.
